Loading...
RDUS logo

Radius Health, Inc.NasdaqGM:RDUS Voorraadrapport

Marktkapitalisatie US$480.8m
Prijs aandeel
n/a
US$10
n.v.t.intrinsieke korting
1Y-27.1%
7D-0.1%
1D
Portefeuillewaarde
​
Bekijk

Radius Health, Inc.

NasdaqGM:RDUS Voorraadrapport

Marktkapitalisatie: US$480.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Radius Health (RDUS) Aandelenoverzicht

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Meer informatie

Beloningen

De winst zal naar verwachting met 53.5% per jaar groeien

Risicoanalyse

Negatief eigen vermogen


RDUS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Radius Health, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Radius Health
Historische aandelenkoersen
Huidige aandelenkoersUS$10.10
52 Week HoogtepuntUS$23.00
52 Week LaagUS$4.97
Bèta0.52
1 maand verandering-0.39%
3 maanden verandering78.76%
1 Jaar Verandering-27.08%
3 jaar verandering-55.21%
5 jaar verandering-71.49%
Verandering sinds IPO26.09%

Recent nieuws en updates

Seeking Alpha • Mar 14

Radius Recycling's Surge Justifies A Reevaluation

Summary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Radius Recycling Will Benefit From Steel Tariffs

Summary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Radius Recycling Stays In The Scrap Pile

Summary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Summary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking Alpha
Seeking Alpha • Aug 11

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

The U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS).  Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11

Recent updates

Seeking Alpha • Mar 14

Radius Recycling's Surge Justifies A Reevaluation

Summary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Radius Recycling Will Benefit From Steel Tariffs

Summary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Radius Recycling Stays In The Scrap Pile

Summary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Summary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking Alpha
Seeking Alpha • Aug 11

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

The U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS).  Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11
Seeking Alpha • Feb 24

Reevaluating Radius Health

Radius Health, Inc. has lost over half its value since the transdermal patch version of its approved osteoporosis therapy (TYMLOS) flunked a Phase 3 trial in December 2021. Its other late-stage asset (elacestrant) just passed a Phase 3 study for breast cancer, but revenue from it will be muted since it divested its developmental and commercial rights to. Some recent small wins for subcutaneously injected TYMLOS, a soon-to-be-investigated CBD asset, and recent beneficial owner buying merited a deeper dive. A full investment analysis follows in the paragraphs below.
Analyseartikel • Feb 23

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...
Analyseartikel • Jan 01

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

It is doubtless a positive to see that the Radius Health, Inc. ( NASDAQ:RDUS ) share price has gained some 58% in the...

Rendement voor aandeelhouders

RDUSUS BiotechsUS Markt
7D-0.1%1.0%1.3%
1Y-27.1%34.2%27.7%

Rendement versus industrie: RDUS presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 34.2 % opleverde.

Rendement versus markt: RDUS presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 27.7 % opleverde.

Prijsvolatiliteit

Is RDUS's price volatile compared to industry and market?
RDUS volatility
RDUS Average Weekly Movement9.8%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stabiele aandelenkoers: De aandelenkoers van RDUS is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van RDUS is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2003293G. Martinradiuspharm.com

Radius Health, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Radius Health zich tot de beurswaarde?
RDUS fundamentele statistieken
MarktkapitalisatieUS$480.77m
Inkomsten(TTM)-US$68.63m
Inkomsten(TTM)US$223.36m
2.2x
P/S-verhouding
-7.0x
Koers/Winstverhouding

Is RDUS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
RDUS resultatenrekening (TTM)
InkomstenUS$223.36m
Kosten van inkomstenUS$19.47m
BrutowinstUS$203.89m
Overige uitgavenUS$272.52m
Inkomsten-US$68.63m

Laatst gerapporteerde inkomsten

Jun 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-1.44
Brutomarge91.28%
Nettowinstmarge-30.72%
Schuld/Eigen Vermogen Verhouding-124.2%

Hoe presteerde RDUS op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2022/08/11 05:35
Aandelenkoers aan het einde van de dag2022/08/11 00:00
Inkomsten2022/06/30
Jaarlijkse inkomsten2021/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Radius Health, Inc. wordt gevolgd door 12 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Gregory HarrisonBofA Global Research
John NewmanCanaccord Genuity
Mara GoldsteinCantor Fitzgerald & Co.